A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

NCT04854434 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Selinexor
DRUG: Pembrolizumab
DRUG: Trifluridine
DRUG: Tipiracil

Sponsor

Karyopharm Therapeutics Inc